Lisette M Wiltink1, Remi A Nout1, Marta Fiocco1, Elma Meershoek-Klein Kranenbarg1, Ina M Jürgenliemk-Schulz1, Jan J Jobsen1, Iris D Nagtegaal1, Harm J T Rutten1, Cornelis J H van de Velde1, Carien L Creutzberg1, Corrie A M Marijnen2. 1. Lisette M. Wiltink, Remi A. Nout, Marta Fiocco, Elma Meershoek-Klein Kranenbarg, Cornelis J.H. van de Velde, Carien L. Creutzberg, and Corrie A.M. Marijnen, Leiden University Medical Center, Leiden; Ina M. Jürgenliemk-Schulz, University Medical Center Utrecht, Utrecht; Jan J. Jobsen, Medisch Spectum Twente, Enschede; Iris D. Nagtegaal, Radboud University Medical Center, Nijmegen; and Harm J.T. Rutten, Catharina Hospital Eindhoven, Eindhoven, the Netherlands. 2. Lisette M. Wiltink, Remi A. Nout, Marta Fiocco, Elma Meershoek-Klein Kranenbarg, Cornelis J.H. van de Velde, Carien L. Creutzberg, and Corrie A.M. Marijnen, Leiden University Medical Center, Leiden; Ina M. Jürgenliemk-Schulz, University Medical Center Utrecht, Utrecht; Jan J. Jobsen, Medisch Spectum Twente, Enschede; Iris D. Nagtegaal, Radboud University Medical Center, Nijmegen; and Harm J.T. Rutten, Catharina Hospital Eindhoven, Eindhoven, the Netherlands. marijnen@lumc.nl.
Abstract
PURPOSE: This study investigated the long-term probability of developing a second cancer in a large pooled cohort of patients treated with surgery with or without radiotherapy (RT). PATIENTS AND METHODS: All second cancers diagnosed in patients included in the TME, PORTEC-1, and PORTEC-2 trials were analyzed. In the TME trial, patients with rectal cancer (n = 1,530) were randomly allocated to preoperative external-beam RT (EBRT; 25 Gy in five fractions) or no RT. In the PORTEC trials, patients with endometrial cancer were randomly assigned to postoperative EBRT (46 Gy in 2-Gy fractions) versus no RT (PORTEC-1; n = 714) or EBRT versus vaginal brachytherapy (VBT; PORTEC-2; n = 427). RESULTS:A total of 2,554 patients were analyzed (median follow-up, 13.0 years; range 1.8 to 21.2 years). No differences were found in second cancer probability between patients who were treated without RT (10- and 15-year rates, 15.8% and 26.5%, respectively) and those treated with EBRT (10- and 15-year rates, 15.4% and 25.6%, respectively) or VBT (10-year rate, 14.9%). In the individual trials, no significant differences were found between treatment arms. All cancer survivors had a higher risk of developing a second cancer compared with an age- and sex-matched general population. The standardized incidence ratio for any second cancer was 2.98 (95% CI, 2.82 to 3.14). CONCLUSION: In this pooled trial cohort of > 2,500 patients with pelvic cancers, those who underwent EBRT or VBT had no higher probability of developing a second cancer than patients who were treated with surgery alone. However, patients with rectal or endometrial cancer had an increased probability of developing a second cancer compared with the general population.
RCT Entities:
PURPOSE: This study investigated the long-term probability of developing a second cancer in a large pooled cohort of patients treated with surgery with or without radiotherapy (RT). PATIENTS AND METHODS: All second cancers diagnosed in patients included in the TME, PORTEC-1, and PORTEC-2 trials were analyzed. In the TME trial, patients with rectal cancer (n = 1,530) were randomly allocated to preoperative external-beam RT (EBRT; 25 Gy in five fractions) or no RT. In the PORTEC trials, patients with endometrial cancer were randomly assigned to postoperative EBRT (46 Gy in 2-Gy fractions) versus no RT (PORTEC-1; n = 714) or EBRT versus vaginal brachytherapy (VBT; PORTEC-2; n = 427). RESULTS: A total of 2,554 patients were analyzed (median follow-up, 13.0 years; range 1.8 to 21.2 years). No differences were found in second cancer probability between patients who were treated without RT (10- and 15-year rates, 15.8% and 26.5%, respectively) and those treated with EBRT (10- and 15-year rates, 15.4% and 25.6%, respectively) or VBT (10-year rate, 14.9%). In the individual trials, no significant differences were found between treatment arms. All cancer survivors had a higher risk of developing a second cancer compared with an age- and sex-matched general population. The standardized incidence ratio for any second cancer was 2.98 (95% CI, 2.82 to 3.14). CONCLUSION: In this pooled trial cohort of > 2,500 patients with pelvic cancers, those who underwent EBRT or VBT had no higher probability of developing a second cancer than patients who were treated with surgery alone. However, patients with rectal or endometrial cancer had an increased probability of developing a second cancer compared with the general population.
Authors: Á Rovirosa; K S Cortés; C Ascaso; A Glickman; S Valdés; A Herreros; C Camacho; J Sánchez; Y Zhang; Y Li; S Sabater; M Arenas; A Torne Journal: Clin Transl Oncol Date: 2018-04-12 Impact factor: 3.405
Authors: Jennifer Rhoades; Monica Hagan Vetter; James L Fisher; David E Cohn; Ritu Salani; Ashley S Felix Journal: Int J Gynecol Cancer Date: 2018-12-21 Impact factor: 3.437
Authors: Hae Lin Cho; Vedang Murthy; Kent W Mouw; Anthony V D'Amico; Paul L Nguyen; Jonathan E Leeman; Edward Christopher Dee Journal: Prostate Date: 2022-06-02 Impact factor: 4.012
Authors: Matthew M Harkenrider; Alec M Block; Kaled M Alektiar; David K Gaffney; Ellen Jones; Ann Klopp; Akila N Viswanathan; William Small Journal: Brachytherapy Date: 2016-05-31 Impact factor: 2.362